SCHEMBL4654099

SCHEMBL4654099

Cc1ncc(CBr)s1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27921498 0.82
SCHEMBL18673935 0.80 SLC6A3 (0.43)
SCHEMBL13142435 0.80 SLC6A3 (0.43)
SCHEMBL1398205 0.78
SCHEMBL3695252 0.76
SCHEMBL128429 0.76
SCHEMBL8241737 0.76
SCHEMBL9368012 0.76
SCHEMBL1107383 0.76
SCHEMBL17714690 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
US-20250346564-A1 INHIBITORS OF PARG ARASE THERAPEUTICS INC (US) 2025-11-13 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
US-12227484-B2 Inhibitors of PARG ARASE THERAPEUTICS INC. (US) 2025-02-18 US disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
EP-4479387-A1 INHIBITORS OF PARG ARase Therapeutics Inc. (US) 2024-12-25 EP disclosed
CN-119013261-A Inhibitors of PARG 雅瑞斯医疗公司 2024-11-22 CN disclosed
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2024-10-31 US disclosed
US-12129221-B2 Difluoro phenyl amide RIP1 inhibitor SIRONAX LTD (KY) 2024-10-29 US disclosed
CN-118638110-A Medicine for treating malignant melanoma 佳木斯大学 2024-09-13 CN disclosed
US-8183270-B2 Insecticidal N-substituted (2-substituted-1,3-thiazol)alkyl sulfoximines DOW AGROSCIENCES, LLC (US) 2012-05-22 US disclosed
US-20110060018-A1 INSECTICIDAL N-SUBSTITUTED (2-SUBSTITUTED-1,3-THIAZOL)ALKYL SULFOXIMINES CORTEVA AGRISCIENCE LLC 2011-03-10 US disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 US disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 US disclosed
WO-2010132999-A1 METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS CHLORION PHARMA, INC. (CA) 2010-11-25 WO disclosed
EP-1644320-B1 INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS LILLY CO ELI (US) 2008-01-16 EP disclosed
US-7265246-B2 Indane derivates as muscarinic receptor agonists ELI LILLY AND COMPANY (US) 2007-09-04 US disclosed
US-20070060587-A1 Indane derivates as muscarinic receptor agonists ELI LILLY AND COMPANY (US) 2007-03-15 US disclosed
EP-1644320-A1 INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2006-04-12 EP disclosed
WO-2005009941-A1 INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2005-02-03 WO disclosed